Highlights

  • Cogstate share price surged by 5% on 22 January 2026, driven by record contracts and diversified revenue streams, delivering annual returns of 94.12%
  • The company’s clinical trial contracts surged 105% in 1H FY26, exceeding guidance
  • Total revenue rose 12% to USD 26.9 million, tracking top-end earnings guidance.
  • Sales from mood, sleep, and neurological conditions jumped to USD 18.7 million, nearly six times the prior half-year.

Cogstate Ltd (ASX:CGS) shares jumped 5% to AUD 2.31 per share on 22 January 2026, amid record clinical trial contracts and diversified revenue streams, lifting one-year returns to 94.12%. The gain followed the company’s announcement of preliminary 1H26 results, showing substantial growth in clinical trial sales contracts driven by non-Alzheimer’s indications and a broader sponsor base.

Record Clinical Trial Contracts Fuel Growth

Cogstate delivered USD 41.7 million in clinical trial sales contracts for the half-year ended 31 December 2025, marking a 105% increase over the previous corresponding period (PCP) and exceeding guidance of USD 37–40 million.

Growth was driven by a broader mix of indications, with USD 18.7 million in sales from mood, sleep, and other neurological conditions, nearly six times higher than the same period last year. Meanwhile, sales related to Alzheimer’s disease trials rose to USD 15.8 million, up 13% on PCP, reflecting the company’s shift toward a more balanced and diversified clinical portfolio.

The expansion into non-Alzheimer’s indications has diversified the company’s portfolio, enhanced revenue quality and increasing confidence in the repeatability of earnings.

Revenue Beats Guidance, Earnings Margins Lifted

Total revenue for 1H FY26 reached USD 26.9 million, up 12% compared to the previous corresponding period (PCP) and exceeding guidance of USD 25–26 million. Preliminary figures indicate that earnings margins are tracking toward the top end of prior guidance, with a gross margin of 50–52%, EBITDA margin of 20–23%, and EBIT margin of 14–17.5%. License fee revenue accounted for 23% of clinical trial revenue, supporting multi-year services income and adding durability to revenue streams.

Looking ahead, total Group contracted future revenue climbed to USD 104.9 million, including USD 21.7 million expected in 2H FY26 and USD 27.0 million projected for FY27, providing greater visibility and confidence in the company’s financial outlook.

Cogstate’s results demonstrate a shift from reliance on large Alzheimer’s trials to a more balanced, diversified clinical portfolio, supporting both revenue growth and sustainability. Investors appear to be responding positively to the company’s expanding market reach and record sales contracts, reflected in the recent share price increase.